Platelet Inhibition to Target Reperfusion Injury (The PITRI trial): Rationale and Study Design
This article is protected by copyright. All rights reserved.
CONCLUSIONS: Age and female gender are associated with lower CFR, and age with worse CFC in an angiographically non-obstructed coronary artery. CFC seems to be less sensitive to variations in clinical and hemodynamic parameters than CFR, and therefore is a promising tool in contemporary clinical decision making in the cardiac catheterization laboratory. PMID: 31951205 [PubMed - as supplied by publisher]
Authors: Chen X, Meng Y, Shao M, Zhang T, Han L, Zhang W, Zhang H, Hai H, Li G Abstract BACKGROUND The aim of the present study was to investigate the clinical predictive value of pre-infarction angina (PIA) combined with mean platelet volume to lymphocyte count ratio (MPVLR) for no-reflow phenomenon and short-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). MATERIAL AND METHODS A total of 1009 STEMI patients who had undergone PCI were enrolled and subdivided into 4 groups based on the occurrence of PIA and the presence of MPVLR ...
CONCLUSIONS: Short-term survival for patients with STEMI and OHCA undergoing emergent coronary angiography and revascularization with TTM in this contemporary, multicenter registry was high and neurologic outcome was good in more than half of patients. PMID: 31941835 [PubMed - as supplied by publisher]
CONCLUSION: In patients with ULMCA disease, PCI was comparable with CABG for long-term MACCE and death rates. The TVR rate was higher in the PCI group. PMID: 31941834 [PubMed - as supplied by publisher]
Mortality after ST elevation myocardial infarction (STEMI) has declined sharply over the last two decades as early reperfusion technology was improved and implemented. Systems of care designed for accurate pre-hospital diagnosis of STEMI and activation of cardiac catheterization laboratories (CCL) have decreased the time to revascularization of the coronary artery.1 –4 Simultaneously, percutaneous coronary intervention (PCI) has improved with enhanced techniques and multiple generations of stent technology increasing success rates and minimizing complications.
Patients with acute myocardial infarction (MI) who underwent percutaneous coronary intervention (PCI) had better outcomes with biodegradable polymer drug-eluting stents (BP-DES) than with second-generation durable polymer drug-eluting stents (DP-DES), a South Korean registry study found.Reuters Health Information
CONCLUSION: In a patient population reflecting routine clinical practice, we found that cases of TVF continued to accrue beyond 2 years after Absorb BVS implantation. PMID: 31953774 [PubMed - as supplied by publisher]
CONCLUSION: Elevated admission glucose levels are associated with impaired microvascular function assessed directly after PPCI in first anterior-wall STEMI. This influence of glucose levels is an acute phenomenon and contributes to microvascular dysfunction through alterations in resting flow and baseline microvascular resistance. PMID: 31953778 [PubMed - as supplied by publisher]
Authors: Wang Z, Gong Y, Fan F, Yang F, Qiu L, Hong T, Huo Y Abstract Objectives: To evaluate the optimal revascularization strategy for patients with coronary artery disease (CAD) and end stage renal disease (ESRD) in the drug-eluting stent (DES) era.Methods: One hundred and twelve patients with ESRD treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) were enrolled from 2007 to 2017. All patients were dialysis-dependent, of which 26 received CABG and 86 underwent PCI. The primary endpoint was all-cause mortality. Secondary endpoints were major adverse cardiovascular even...
AbstractBackgroundImpaired renal function (IRF) is associated with increased risks of both ischemic and bleeding events. Ticagrelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in those with versus without IRF.MethodsA pre-specified sub-analysis of the randomized GLOBAL LEADERS trial (n = 15,991) comparing the experimental strategy of 23-month ticagrelor monotherapy (after 1-month ticagrelor and aspirin dual anti-platelet therapy [DAPT]) with 12-month DAPT followed by 12-month aspirin after percutaneous coronary intervention (PCI) in ACS and sta...